

An approach to cough in older people

Cough is one of the commonest symptoms presenting to the primary care clinician.¹ Many coughs are benign and self limiting. However the varied aetiologies of cough and the possibility of an underlying sinister diagnosis can make cough a challenging symptom to manage in primary and secondary care.

Dr Kunal Chawathey GP Registrar, Bournbrook Varsity Medical Centre, 1A Alton Road, Selly Oak

Dr Elizabeth Croton GP, Bournbrook Varsity Medical Centre, 1A Alton Road, Selly Oak

*Email kunalchawathey@doctors.org.uk

Cough is a forceful expulsive manoeuvre against a closed glottis and associated with a characteristic sound.¹ Acute cough typically lasts for less than three weeks. Chronic cough lasts for more than eight weeks.

It is important for the clinician to actively look for clues suggesting a more serious cause for cough, especially whilst assessing an elderly patient. Lung cancer is rarely diagnosed in people younger than 40 years, but the incidence rises steeply thereafter, peaking in people aged 80–84 years. Most cases (87%) occur in people over the age of 60 years.²

Approach to a patient with cough

History

A good history is an essential first step in the approach to cough. Cough due to reflux may be aggravated by bending over or lying down. Asthma, infection or heart failure can cause nocturnal cough that may wake the patient. Viral infection

enhances cough reflex sensitivity and may unmask subclinical bronchial hyper-responsiveness or reflux.³ Significant sputum production suggests a primary pulmonary pathology. A “honking” or “barking” cough that disappears with sleep is typical of a psychogenic or habit cough.¹

A relevant occupational history is important as work place sensitizers can lead to intermittent or chronic cough. With the increased public awareness regarding the hazards of asbestos exposure, patients are often aware of personal previous occupational risk. Risky occupations include ship building, plumbing, roofing, and work in the construction industry.

Angiotensin converting enzyme inhibitors also increase sensitivity to cough reflex and cause a dry irritating cough in 10–22% of patients.⁴ The median time of resolution of cough on cessation of the drug is 26 days, although it can last longer (up to 40 weeks) in some patients.^{5,6}

Cough associated with night sweats and weight loss may be due to tuberculosis, especially in the context of known exposure or travel to

endemic areas. Breathlessness and associated cough can be one of the myriad of symptoms experienced by the patient with underlying lymphoma along with lymphadenopathy and systemic symptoms of sweating and fatigue.

Persistent hoarseness of the voice may be associated with a secondary cough. This may be due to laryngeal pathologies like vocal nodules, polyps or laryngeal carcinoma. Malignant invasion of either the vagus or recurrent laryngeal nerves can occur with cancers of the thyroid, lung and oesophagus leading to hoarseness of voice and secondary cough.

More than 90% of patients with lung cancer are symptomatic at the time of diagnosis.⁷ According to one study, the frequency of initial symptoms in patients with bronchogenic carcinoma were: cough (75%), weight loss (64%), dyspnoea (55%), chest pain (43%) and hemoptysis (34%).⁸ However, subsequent studies have shown different frequencies of the above symptoms.

Tobacco smoking is well established as the main cause of lung cancer and about 90% of

Box 1: Common causes of cough in the adult population**Post viral cough**

History of preceding respiratory illness with a non-productive cough that lasts for up to eight weeks

GORD

Cough that occurs whilst eating and after food. It may also occur whilst bending down or when recumbent

Post nasal drip syndrome (PNDS)

Mucoid nasal secretions containing inflammatory mediators stimulate the pharynx inducing cough¹¹ that responds to decongestants, topical steroids and antihistamines¹²

Drugs (ACE inhibitors)

Drugs can cause cough in up to 20% of patients.⁴ ACE inhibitor cough can occur as early as day two of therapy and can last for a few weeks after cessation

Smoking

Loss of motion of cilia that line the respiratory tree result in stagnation of sputum followed by cough

Chronic bronchitis

Productive cough for at least three months over two consecutive years. Co-existent smoking history

Cough variant asthma

Nocturnal non-productive cough in the absence of wheeze or dyspnoea. Often a history of atopy. Symptoms usually respond to corticosteroid trial.

cases are thought to be tobacco related. There is a clear dose-response relation between lung-cancer risk, the number of cigarettes smoked per day, degree of inhalation and age at initiation of smoking. Someone who has smoked all their life has a lung-cancer risk 20–30 times greater than a non-smoker.⁹

Physical examination

The physical examination of the patient with chronic cough may demonstrate clinical signs pointing towards a particular

condition. For example, finger clubbing in a smoker with evidence of a pleural effusion or lobar collapse on examination strongly suggests a diagnosis of bronchogenic carcinoma. The clinician may be able to demonstrate signs of obstructive lung disease, pulmonary fibrosis, bronchiectasis or cardiac failure.

A good general examination is extremely important in dealing with an isolated symptom such as cough, but this can be challenging within the constraints of the general practice consultation.

Findings like clubbing, pallor, lymphadenopathy, neck swellings, thenar wasting, and the classic but rare Horner's syndrome can provide vital clues to the underlying aetiology.

Investigation

A chest radiograph should be performed in patients with chronic cough and those with acute cough with atypical symptoms like haemoptysis, chest pain and weight loss.

The National Cancer Institute Early Lung Cancer Group (1984) demonstrated that the sensitivity of chest radiography (CXR) is 54% when "suspicious" CXRs are coded as positive with a corresponding specificity of 99%. When indeterminate CXRs are considered positive, the sensitivity of CXR increases to 84% with a specificity of 90%. However, false negative CXR results continue to be a significant problem¹⁰ and therefore clinical judgment must prevail in a patient with a suspicious history and signs of lung cancer in the presence of a normal chest x-ray. Onward referral for diagnostic investigation such as bronchoscopy should take place in these patients.

Spirometry can help to classify patients with suspected lung disease into two broad categories. Those with an obstructive pattern on spirometry should have their FEV1 (forced expiratory volume in one second) measured before and after inhalation of a short acting b2-agonist such as salbutamol to demonstrate reversibility. Spirometry may also reveal a restrictive picture as in pulmonary fibrosis (an intrinsic lung parenchymal disease) or

TOVIAZ[®] Abbreviated Prescribing Information: (See Toviaz Summary of Product characteristics for full Prescribing Information).

Presentation: Prolonged-release tablets containing fesoterodine fumarate. The 4mg is light blue, oval, engraved FS containing 3.1mg of fesoterodine. The 8mg is blue, oval, engraved FT containing 6.2mg of fesoterodine.

Indications: Symptomatic treatment of urge incontinence and/or urinary frequency and/or urgency that may occur in patients with overactive bladder syndrome. **Dosage:** Adults (including Elderly): 4mg once daily. The tablet should be taken whole with some liquid. The dose may be increased to max daily dose of 8mg once daily. The max dose in patients with severe renal impairment or moderate hepatic impairment is 4mg. Treatment should be re-evaluated after 8 weeks. Children: Not recommended. Cautious dose increase recommended in patients with mild or moderate renal impairment or mild hepatic impairment. Max dose with patients using moderate CYP3A4 inhibitors with mild or moderate renal impairment or mild hepatic impairment is 4mg. Use should be avoided in patients with mild renal or hepatic impairment using potent CYP3A4 inhibitors, or patients with severe renal impairment or moderate hepatic impairment using moderate CYP3A4 inhibitors. In patients receiving concomitant potent CYP3A4 inhibitors the max. daily dose is 4mg. **Contraindications:** Hypersensitivity to fesoterodine, soya, peanut or excipients, urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe ulcerative colitis, toxic megacolon. Concomitant use of potent CYP3A4 inhibitors in patients with moderate or severe renal impairment, or patients with moderate hepatic impairment.

Warnings and Precautions: Use with caution in patients with significant bladder outlet obstruction at risk of urinary retention, gastrointestinal obstructive disorders, e.g. pyloric stenosis, gastro-oesophageal reflux, concurrent medicinal products that may cause or exacerbate oesophagitis, autonomic neuropathy, controlled narrow-angle glaucoma, decreased gastrointestinal motility. Toviaz should not be used in patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Fesoterodine should be used with caution in patients with risk factors for QT-prolongation including: electrolyte disturbances, bradycardia and concomitant administration of drugs known to prolong QT-interval, relevant pre-existing cardiac diseases especially when taking potent CYP3A4 inhibitors. Concomitant treatment with potent CYP2D6 inhibitors may increase exposure, and the dose should be increased with caution especially in patients with hepatic or renal impairment. Patients with a combination of hepatic or renal impairment or concomitant administration of potent or moderate CYP3A4 inhibitors or potent CYP2D6 inhibitors are expected to have additional exposure increases and dose dependant side effects – dose increase to 8mg where possible should be preceded by an evaluation of response and tolerability. Organic reasons for urge, frequency or overactive bladder should be considered before treatment. If angioedema occurs with fesoterodine use, fesoterodine should be discontinued and appropriate therapy promptly provided.

Drug Interactions: Concomitant use of other antimuscarinic agents and medicinal products with anticholinergic properties or with strong inhibitors of CYP3A4, may lead to more pronounced therapeutic and side-effects. Induction of CYP3A4 may lead to subtherapeutic plasma levels. Concomitant use with CYP3A4 inducers is not recommended. Co-administration of Toviaz with potent CYP2D6 inhibitors may lead to increased exposure and adverse events. A dose reduction to 4mg may be required. Fesoterodine may reduce the effect of products that stimulate the motility of the gastro-intestinal tract. **Pregnancy & Lactation:** Not recommended. See Full Prescribing Information. **Side Effects:** In clinical trials, the most commonly reported adverse reaction was dry mouth. Common reported events include dizziness, headache, dry eye, dry throat, abdominal pain, diarrhoea, dyspepsia, constipation, nausea, dysuria, insomnia. Other side-effects include uncommon; tachycardia, palpitations, somnolence, blurred vision, vertigo, urinary retention (including feeling of residual urine), ALT increased, GGT increased; rare angioedema, confusional state. Refer to SmPC for information on other side effects. **Driving and operating machinery:** The ability to drive and use machines may be affected by blurred vision, dizziness and somnolence, see side effects. **Overdose:** Treat with gastric lavage and give activated charcoal. Treat symptomatically. **Legal Category:** POM.

Marketing authorisation holder: Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK. **Package quantities, Marketing Authorisation numbers and basic NHS price:** TOVIAZ 4mg, 28 prolonged-release tablets, EU/1/07/386/003 £25.78; TOVIAZ 8mg, 28 prolonged-release tablets, EU/1/07/386/008 £25.78. **Further information is available on request from:** Medical Information at Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS, UK. Tel: +44 (0) 1304 616161

Date of Preparation: October 2011. **Company reference:** TV6_1.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

Box 2: Serious conditions presenting with cough

Respiratory causes

Bronchogenic carcinoma

Mesothelioma

Laryngeal carcinoma

Tuberculosis

Pneumonia

Pulmonary embolism

Foreign body inhalation

Interstitial lung disease

Cardiac causes

Left ventricular failure

Mitral stenosis

Pericarditis with effusion

Other causes

Oesophageal carcinoma

Thoracic aortic aneurysm

Lymphoma

disease extrinsic to the lung parenchyma such as neuromuscular disorders.

Blood tests and sputum examination may reveal information such as pneumonia, tuberculosis or secondary polycythemia. Bronchoscopy enables tissue diagnosis while oesophageal pH studies can confirm reflux disease. High resolution CT scanning of the thorax can demonstrate lung parenchymal, interstitial or pleural disease.

Management

Early detection of any serious illness is crucial to improve chances of survival. It is therefore imperative to have a high index of clinical suspicion and a low threshold for investigation in at risk patients who present with nonspecific symptoms such as cough.

In most cases where lung cancer is suspected it is appropriate to arrange an urgent chest x-ray before urgent referral to a chest physician.⁷




Figure 1. Treatment algorithm

Urgent referral for a chest x-ray should be conducted for:

- Haemoptysis
- Unexplained or persistent (more than three weeks) cough
- Chest/shoulder pain
- Dyspnoea
- Weight loss
- Chest signs
- Hoarseness
- Finger clubbing
- Features suggestive of metastasis from a lung cancer (eg. brain, bone, liver or skin)
- Persistent cervical/supraclavicular lymphadenopathy
- Fatigue in a smoker over 50 years of age.⁷

Urgent referral to a chest physician should be for any of the following:

- Chest x-ray suggestive/suspicious of lung cancer (including pleural effusion and slowly resolving consolidation)
- Persistent haemoptysis in smokers/ex-smokers over 40 years of age
- Signs of superior vena caval obstruction (swelling of face/neck with fixed elevation of jugular venous pressure)
- Stridor (consider emergency referral)
- Any of the symptoms in the previous table persisting for longer than six weeks despite normal chest x-ray.⁷

In the presence of associated signs and symptoms or if the diagnosis is obvious, management of cough can be straightforward. However, once in a while we are left with a solitary cough with no supporting findings. In such a situation, it is reasonable to perform basic investigations and

commence a trial of treatment simultaneously.

Bearing in mind that the common causes of chronic cough are post nasal drip, GORD and asthma, the following algorithm can be helpful in deciding to manage these patients. (Figure 1)

Conclusion

An experienced clinician would use pattern recognition in identifying the cause of cough. But when clinical findings do not fit into a particular pattern, most of us, consciously or subconsciously, use the hypothetico-deductive model for problem solving. We start with a hypothesis (working diagnosis) based on history and clinical findings that we attempt to prove (or disprove) with investigations or trial of a treatment. Lack of available information results in speculations (differential diagnoses), that we then attempt to work through. This speculative approach brings the concept of art into science.

Conflict of interest: none declared

References

1. British Thoracic Society Cough Guideline Group; British Thoracic Society. *Thorax* 2006; **61** (Suppl 1) i1–i24
2. Office for National Statistics, Cancer Statistics registrations: registrations of cancer diagnosed in 2007, England info. cancerresearchuk.org/cancerstats/types/lung/incidence/ Accessed 12/11/11
3. O'Connell F, Thomas VE, Studham JM, et al. Capsaicin

cough sensitivity increases during upper respiratory infection. *Respir Med* 1996; **90**: 279–86

4. Tumanan-Mendoza BA, Dans AL, Villacin LL, et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. *J Clin Epidemiol* 2007; **60**(6): 547–53.
5. Yeo WW, Foster G, Ramsay LE. Prevalence of persistent cough during longterm enalapril treatment: controlled study versus nifedipine. *Q J Med* 1991; **80**: 763–70
6. Ojoo JC, Kastelik JA, Morice AH. Duration of angiotensin converting enzyme inhibitor (ACEI) induced cough (abstract). *Thorax* 2001; **56**(Suppl III): iii72
7. <http://www.scotland.gov.uk/Publications/2002/05/14862/5419>; Scottish Referral Guidelines for Suspected Cancer Accessed 10/11/11
8. Hyde L, Hyde C. Clinical Manifestations of Lung Cancer. *Chest* 1974; **65**(3): 299–306 <http://chestjournal.chestpubs.org/content/65/3/299> Accessed 10/11/11
9. Tyczynski JE, Bray F, Parkin DM. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. *Lancet Oncol* 2003; **4**(1): 45–55
10. Early Lung Cancer Cooperative Study Group. Early lung cancer detection: summary and conclusions. *Am Rev Respir Dis* 1984; **130**: 565–70
11. Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. *Lancet* 2008; **371**(9621): 1364–74
12. Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. *Chest* 2006; **129**(1 Suppl): 59S–62S